Sign in Subscribe
Cancer

Breakthrough in Cancer Treatment: Engineered Nanovehicles Show Promise

Strategic Insights

— 1 min read

Researchers at Westlake University in Hangzhou, People's Republic of China, have made a significant discovery in the field of cancer treatment. By engineering a pluripotential biomimetic nanovehicle (ADM) that can target tumors and modulate the tumor immune microenvironment (TME), they have developed a platform that can potentiate anti-tumor immunity. This breakthrough has the potential to enhance cancer chemoimmunotherapy and improve treatment outcomes for patients.

Key Takeaways:

  • The engineered nanovehicle, called ADM, is designed to target tumors and modulate the TME, making it more susceptible to anti-tumor immunity.
  • ADM exhibits high affinity for autologous tumors and can improve the accumulation of drugs into tumor tissues.
  • The nanovehicle can metabolically inhibit extracellular H+ production to remodel the acidic immunosuppressive TME, creating a tumor antigen pool that potentiates anti-tumor immune response.
  • ADM facilitates tumor-targeted delivery of doxorubicin (DOX) and synergizes DOX-mediated immunogenic cell death (ICD) induction with a synergistic TME modulating feat.
  • The rationally designed pluripotent biomimetic nanovehicle orchestrates precision drug delivery with simultaneous immunomodulation, furnishing a compendious yet powerful platform for augmenting anti-tumor immunity.

Statistics:

  • The research was funded by the National Natural Science Foundation of China (NSFC), Natural Science Foundation of Zhejiang Province, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents, Zhejiang Medical Key Discipline Foundation, Hangzhou Medical Key Discipline Foundation, and Construction Fund of Key Medical Disciplines of Hangzhou.
  • The DOI for the research paper is 10.1016/j.cesj.2025.09.017.
  • The journal where the research was published is Chemical Engineering Journal, Volume 523, 2025.
  • The authors of the study include Nengming Lin, Nan Wang, Jiahe Wu, Bo Zhang, Mingjian Zhu, Shengfei Yang, Manning Zhu, Lan Ma, Xunqi Zhang, Jianqing Gao, and Donghang Xu.

Sources:

  • Dual-targeting Pluripotential Biomimetic Nanovehicle Modulates Tumor Immune Microenvironment for Potentiated Cancer Chemoimmunotherapy (Chemical Engineering Journal, 2025;523)
  • Chemical Engineering Journal (Elsevier - www.elsevier.com; Chemical Engineering Journal - www.journals.elsevier.com/chemical-engineering-journal/)
  • NewsRx. Findings from Westlake University Provides New Data about Cancer (Dual-targeting Pluripotential Biomimetic Nanovehicle Modulates Tumor Immune Microenvironment for Potentiated Cancer Chemoimmunotherapy). Cancer Weekly. November 4, 2025; p 169.

Read more